- Home
- CURV vs TRVI Comparison
CURV vs TRVI Comparison
Compare CURV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- TRVI
- Stock Information
- Founded
- CURV 2001
- TRVI 2011
- Country
- CURV United States
- TRVI United States
- Employees
- CURV N/A
- TRVI N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CURV Consumer Discretionary
- TRVI Health Care
- Exchange
- CURV Nasdaq
- TRVI Nasdaq
- Market Cap
- CURV N/A
- TRVI 383.4M
- IPO Year
- CURV 2021
- TRVI 2019
- Fundamental
- Price
- CURV $5.61
- TRVI $6.66
- Analyst Decision
- CURV Hold
- TRVI Strong Buy
- Analyst Count
- CURV 4
- TRVI 8
- Target Price
- CURV $5.00
- TRVI $17.56
- AVG Volume (30 Days)
- CURV 303.7K
- TRVI 4.3M
- Earning Date
- CURV 03-20-2025
- TRVI 03-18-2025
- Dividend Yield
- CURV N/A
- TRVI N/A
- EPS Growth
- CURV 36.36
- TRVI N/A
- EPS
- CURV 0.15
- TRVI N/A
- Revenue
- CURV $1,103,737,000.00
- TRVI N/A
- Revenue This Year
- CURV $1.84
- TRVI N/A
- Revenue Next Year
- CURV $1.16
- TRVI N/A
- P/E Ratio
- CURV $37.60
- TRVI N/A
- Revenue Growth
- CURV N/A
- TRVI N/A
- 52 Week Low
- CURV $2.18
- TRVI $2.30
- 52 Week High
- CURV $9.14
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- CURV 47.25
- TRVI 67.49
- Support Level
- CURV $5.43
- TRVI $4.24
- Resistance Level
- CURV $6.95
- TRVI $7.14
- Average True Range (ATR)
- CURV 0.46
- TRVI 0.49
- MACD
- CURV 0.04
- TRVI 0.06
- Stochastic Oscillator
- CURV 39.05
- TRVI 68.57
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.